PlainBillCongress, translated.Legislation. Context. Public interest.Congressional Research Service
No official summary is available in the imported record yet.
People & committees
Rep. Perry, Scott [R-PA-10] · R–PA
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Subcommittee on Health.
Referred to the Committee on Armed Services, and in addition to the Committee on Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Armed Services, and in addition to the Committee on Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Sep 19, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1947 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1947 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1947 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1947 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2025-03-06 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
The proposed TREAT PTSD Act would require health systems serving veterans and military members to provide stellate ganglion block to eligible patients with post-traumatic stress disorder (PTSD). Patients would have to choose the treatment after a qualified health care provider explains its risks and benefits. The bill would also require updated treatment guidance explaining its availability and medical reasons for or against its use.
This Act may be cited as the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act or the TREAT PTSD Act.
The Secretary shall furnish stellate ganglion block to any veteran who— (1) is enrolled in the patient enrollment system under section 1705 of this title; (2) has been diagnosed with post-traumatic stress disorder; and (3) has elected to receive stellate ganglion block after being informed by a qualified health care provider of the risks and benefits of stellate ganglion block.
The Secretary shall furnish stellate ganglion block to any member of the Armed Forces (including the reserve components) who is performing or has performed active service and who— (1) is enrolled in the TRICARE program under chapter 55 of this title; (2) has been diagnosed with post-traumatic stress disorder; and (3) has elected to receive stellate ganglion block after being informed by a qualified health care provider of the risks and benefits of stellate ganglion block.
to ensure the guideline— (A) reflects the availability of stellate ganglion block as a therapy option; and (B) includes information on the clinical indicators and contraindicators for such therapy option.
For veterans, the bill would add a requirement to provide stellate ganglion block when the veteran is enrolled in the patient enrollment system referenced in section 1705, has a PTSD diagnosis, and chooses the treatment after receiving information about its risks and benefits from a qualified health care provider.
1720M. Provision of stellate ganglion block for certain veterans (a) In general The Secretary shall furnish stellate ganglion block to any veteran who— (1) is enrolled in the patient enrollment system under section 1705 of this title; (2) has been diagnosed with post-traumatic stress disorder; and (3) has elected to receive stellate ganglion block after being informed by a qualified health care provider of the risks and benefits of stellate ganglion block.
For military members, including members of reserve components, the requirement would cover those performing or having performed active service who are enrolled in TRICARE, have a PTSD diagnosis, and choose the treatment after a qualified provider explains its risks and benefits. TRICARE is the military health program referenced by the bill.
1074p. Provision of stellate ganglion block for certain members (a) In general The Secretary shall furnish stellate ganglion block to any member of the Armed Forces (including the reserve components) who is performing or has performed active service and who— (1) is enrolled in the TRICARE program under chapter 55 of this title; (2) has been diagnosed with post-traumatic stress disorder; and (3) has elected to receive stellate ganglion block after being informed by a qualified health care provider of the risks and benefits of stellate ganglion block.
The bill would permit treatment through department medical facilities. It would also permit treatment for veterans through providers specified in section 1703(c), and treatment for military members through qualified providers participating in a department-administered TRICARE health insurance program. These delivery options would be discretionary; the requirement to furnish treatment to eligible patients would be mandatory.
The Secretary shall furnish stellate ganglion block to any veteran who—
The Secretary may furnish stellate ganglion block under subsection (a) through a medical facility of the Department or through a health care provider specified in section 1703(c) of this title.
The Secretary shall furnish stellate ganglion block to any member of the Armed Forces (including the reserve components) who is performing or has performed active service and who—
The Secretary may furnish stellate ganglion block under subsection (a) through a medical facility of the Department or through a qualified health care provider participating in a Department administered TRICARE health insurance program.
Within 180 days after enactment, the Secretaries of Veterans Affairs and Defense would have to update their joint PTSD treatment guideline, or its successor. The update would describe stellate ganglion block as an available treatment option and include medical indicators supporting its use and contraindicators—medical reasons against its use.
Not later than 180 days after the date of the enactment of this Act, the Secretary of Veterans Affairs and the Secretary of Defense shall update the guideline published jointly by the Secretaries and titled the VA/DOD Clinical Practice Guideline (CPG) for the Management of PTSD (or such successor guideline) to ensure the guideline— (A) reflects the availability of stellate ganglion block as a therapy option; and (B) includes information on the clinical indicators and contraindicators for such therapy option.
After updating the guideline, the Secretaries would have to notify the congressional defense committees and the House and Senate Veterans’ Affairs Committees.
(2) Notification Upon updating the guideline under paragraph (1), the Secretaries shall notify the appropriate congressional committees of such update. (3) Appropriate congressional committees defined In this subsection, the term appropriate congressional committees means— (A) the congressional defense committees (as such term is defined in section 101 of title 10, United States Code); and (B) the Committees on Veterans’ Affairs of the House of Representatives and the Senate.
The amendments establishing treatment requirements for veterans and military members would take effect 180 days after enactment. This is a deadline measured from enactment, not a fixed calendar date.
(d) Effective date The amendments made by subsections (a) and (b) shall take effect on the date that is 180 days after the date of the enactment of this Act.
The supplied September 19, 2026 source snapshot records introduction in the House and referral to the Armed Services and Veterans’ Affairs Committees on March 6, 2025, followed by referral to the Subcommittee on Health on March 27, 2025. These entries do not establish whether the bill later advanced or became law.
Source snapshot updated 2026-09-19T23:38:28Z.
2025-03-06: Introduced in House
2025-03-06: Referred to the Committee on Armed Services, and in addition to the Committee on Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-03-27: Referred to the Subcommittee on Health.
A closer look
Reviewed version: Introduced in House · 2025-03-06. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy change attached to appropriations was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish what appears in other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for a particular recipient or place was identified in the complete supplied introduced text. This conclusion is limited to that version; formal earmark disclosures and accompanying materials are not supplied.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No materially narrow carve-out, special exemption, or preferential exception was identified in the complete supplied introduced text. Eligibility for the bill’s central treatment program constitutes ordinary coverage of its intended beneficiaries. This conclusion is limited to the supplied version.
Full text preserved for this analysis. Legislative record snapshot: Sep 19, 2026. How PlainBill uses AI